Physiomics uses Virtual Tumour and other industry standard technologies to predict the effects of cancer treatment regimes for the biopharma industry.

How can we help you?

Solve cancer drug development challenges

Optimise combination regimens, manage drug resistance, scale up from mouse to human, predict immune-oncology effects

Learn more

See our range of cancer modelling experience

Find out more about drug targets, drug types and cell lines where we have significant experience

Learn more

Learn about Virtual Tumour

Flexible in-silico cell-cycle based model combining PK and PD effects to predict cancer growth inhibition.

Learn more

Any other questions?

If you don’t see what you need here, please contact us by clicking on the link below.

Contact Us

News & publications

Conference attendance and presentation

Physiomics to present on personalised medicine and Virtual Tumour™ developments at AACR 2019 meeting Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict…

BioNeex Expert Interview with Physiomics

Dr Hitesh Mistry, Principal Consultant for Physiomics was interviewed by BioNeex on Cancer drug licensing: How to use your data to make yourself an attractive…

Interim Results for the period ended 31st December 2018

Oxford, UK, 21 February 2019: The Board of Physiomics Plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the…

Editorial Appointment

Physiomics plc (AIM: PYC), is pleased to announce that one of its long-term consultants and collaborators, Dr Hitesh Mistry, has been appointed to the…